Short Report: Pediatric Cutaneous Leishmaniasis in an Endemic Region in India

Saurabh Agrawal, Kanika Khandelwal, Ram A. Bumb, Steve Oghumu, Poonam Salotra, and Abhay R. Satoskar*
Department of Dermatology, Sardar Patel Medical College, Bikaner, Rajasthan, India; Department of Molecular Biology, Indian Council of Medical Research, New Delhi, India; Department of Pathology and Microbiology, Ohio State University, Columbus, Ohio

Abstract. Cutaneous leishmaniasis (CL) is endemic in the Bikaner region situated in the Thar Desert of Rajasthan, India. This study describes clinicoepidemiological data of pediatric CL in pre-school children (0–5 years of age) from this region during 2001–2012. In total, 151 patients with 217 lesions were reported during the study period. The mean age of the study group was 3.29 ± 1.43 years (0.25–5 years), with many (41.7%) cases being in the age group of 2–4 years. Face was the most common site involved, and morphologically, the lesions were either plaque type or papulonodular. Smear for parasitological examination was positive in 84 (70%) of 120 cases, and histopathologic examination confirmed CL in 10 (55.55%) of 18 cases. Parasite species identification conducted for 13 randomly selected patients by polymerase chain reaction identified Leishmania tropica as the causative species. Intraleosional sodium stibogluconate was the most commonly used treatment and found to be well-tolerated. Other therapies that were effective included oral rifampicin, oral dapsone, radiofrequency heat therapy (RFHT), and combinations of the three therapies.

INTRODUCTION

Leishmaniasis is a widespread tropical infectious disease caused by a hemoflagellate protozoan parasite of the Leishmania genus. The disease manifests mainly in three forms: visceral (L. donovani and L. infantum), cutaneous (L. tropica, L. major, L. aethiopica, L. mexicana, L. guyanensis, L. peruvianna, and L. amazonensis), and mucocutaneous (L. subgenus Vianna bresilienisis and L. subgenus Vianna guyanensis).1 Cutaneous leishmaniasis (CL) is the most common type; approximately 1.5 million new cases occur annually, and 90% of these cases are in Asia, the Middle East, north Africa, and South America.2 In India, CL is reported primarily from the Bikaner region situated in the Thar Desert of the Rajasthan State.3 L. tropica has been established as the causative organism in Bikaner in both rural and urban areas.4 CL affects all age groups, and children are as susceptible to the parasite as adults.5 In established endemic areas, the prevalence of CL typically increases with age, up to about 15 years, after which time prevalence levels off, presumably because of the acquisition of immunity.6 Many studies have been published that describe the epidemiologic profiles, therapeutic modalities, and clinical outcomes of CL in the pediatric age group in various parts of world where CL is endemic.7–12 Most of these studies have been done in the age group of 0–14 years.

Confirmation of diagnosis in pre-school children is difficult, because invasive procedures, like cutaneous biopsy/slit skin smear, are difficult to perform. A clinicoepidemiological study focused on pre-school children will lead to a better understanding of the clinical presentation of this disease and help in the early diagnosis and proper management of CL in this age group. This study describes the epidemiologic characteristics of CL in pre-school children. To the best of our knowledge, there has been no such study from India in the past.

MATERIALS AND METHODS

The study was a retrospective epidemiological study conducted from January of 2001 to December of 2012 at the Department of Dermatology, Sardar Patel Medical College, Bikaner, Rajasthan, India, and it included all patients of CL. Detailed data analysis of pre-school children with CL for the same time period was done separately. CL was diagnosed on the basis of clinical features and demographic profile. Additional confirmation of diagnosis was done by parasitological smear in a majority of patients and histopathological examination in a few of the patients. Demographic parameters, such as age, sex, and geographic location; family history of CL; duration of illness; clinical features, such as number, site, size, and type of the lesions; routine laboratory investigations; results of the slit skin smear and histopathologic finding; treatment administered; and outcome were noted on a printed pro forma.

Depending on the age, numbers of lesions, and sites of lesions, patients were treated with different treatment modalities either alone or in combination. The following treatments were administered on a case-by-case basis.

(1) Intraleosional injections of sodium stibogluconate (SSG; Albert David Ltd., Kolkata, India) at a dose of 0.5 mL/cm² (100 mg/mL solution) one or two times per week for five to seven injections.

(2) For topical radiofrequency heat therapy (RFHT), the controlled heat was applied locally at 50°C for 30 seconds under local anesthesia with a localized current field radio frequency generator (ThermoMed 1.8 device; Thermosurgery Technologies, Inc., Phoenix, AZ).

(3) Oral rifampicin at a dosage of 20 mg/kg body weight per day for 4–6 weeks (Glaxo Smith Kline Pharmaceuticals Ltd., Maharashtra, India).

(4) Oral dapsone at a dose of 20 mg/kg per day for 4–6 weeks (Glaxo Smith Kline Pharmaceuticals Ltd.).

Complete cure was defined as total re-epithelization of the lesion (flattening of the lesion and absence of signs of inflammation) with or without scarring and a negative skin smear. Patients were followed up initially at an interval of 2 weeks and thereafter, on a monthly basis until complete cure. Slt skin smear was taken from completely healed lesions after completion of treatment in cases that were positive at initial diagnosis.

RESULTS

In total, 151 (10.3%) patients in the age group of 0–5 years were clinically diagnosed with CL from January of 2001 to
December of 2012 of a total of 1,466 cases reported during the same period. The demographic profile is summarized in Table 1. The mean age was 3.29 ± 1.43 years (0.25–5 years), with the majority (41.7%) of cases being in the age group of 2–4 years. The sex ratio (male/female) was 1.56, with 92 male patients and 59 female patients. Family history of CL was observed in 16 cases (10.9%). The incidence in winter (between November and March) was more than in the summer season (between April and October). The lowest number of cases for a month were reported in October (3 cases), and the maximum number of cases was in March (25 cases).

In total, 217 lesions were present in 151 patients, with the mean number of lesions being 1.43 (±0.93, range = 1–8) per patient. Single lesions were most commonly seen (i.e., in 109 patients [72.2%]), whereas double and multiple lesions were recorded in 30 (19.9%) and 12 (7.9%) patients, respectively. Clinically, the lesions were either plaque type (75.5%) or papulonodular (24.5%). The face was the most commonly involved site (72.18%). Upper limb, lower limb, and trunk were affected in 9.93%, 7.94%, and 1.32% cases, respectively, whereas multiple sites were involved in 8.63% of cases (Figure 1). The details of clinical features are provided in Table 2.

The mean duration of the cutaneous lesions before presentation was 17.88 ± 1.18 weeks (range = 2–48 weeks), whereas the sizes of the lesions varied from 0.50 to 6 cm, with a mean value of 2.42 cm (±1.63 cm). Smears for parasitologic examination were performed in 120 patients, and they were positive in 84 (70%) patients. Skin biopsies were performed in 18 patients, of which 10 (55.5%) patients were positive for *Leishmania*. Histopathology in all cases showed granulomatous inflammation in the dermis with the presence of parasitized macrophages and epithelioid and plasma cells along with lymphomononuclear infiltrate. Internal transcribed spacer region 1 restriction fragment length polymorphism polymerase chain reaction (PCR) and kinetoplast DNA PCR were performed in 13 randomly selected patients, and all patients were positive for *L. tropica*.

In total, 148 (98.01%) patients received treatment. Intralosional SSG was most commonly used (58 patients; 38.4%), and it was well-tolerated in all patients. Heat therapy was administered to 14 (9.4%) patients. Fifty (33.1%) patients received oral rifampicin. Three (1.9%) patients were treated with oral dapsone, whereas both dapsone and rifampicin were given orally in 11 (7.3%) patients. Twelve (7.9%) patients received a combination of systemic and local therapies in the form of intralosional injections of SSG and oral rifampicin.

Nine patients were lost to follow-up, whereas response to treatment was recorded in 139 (92.1%) patients. Complete cure of the lesions was obtained within an average period of 9.7 weeks (±3.3 weeks, range = 4–20 weeks). Slit skin smears were performed in 80 (of 84) completely cured cases that were positive at the time of diagnosis, and they were found to be

<table>
<thead>
<tr>
<th>Table 1 Demographic profile of CL patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age group (years)</td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td>0–2</td>
</tr>
<tr>
<td>2–4</td>
</tr>
<tr>
<td>4–5</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

Figure 1. Clinical manifestations of CL in pre-school children at Bikaner. (A) Nodular. (B) Crusted plaque. (C) Ulcerative nodule. (D) Ulcerative plaque.
negative in all cases. The mean time for healing varied with the treatment modality used. Complete cure was seen in 125 (82.78%) patients at 20 weeks. Complete cure with local therapies (i.e., intralesional SSG and RFHT) was observed in 84.4% and 91.8% of patients, respectively. Similarly, with oral rifampicin, oral dapsone, and a combination of rifampicin and dapsone, complete healing was recorded in 82%, 66.67%, and 90.1% of patients respectively. The combination of intralesional SSG and oral rifampicin was effective in 100% of cases.

**DISCUSSION**

Although only a few studies have been published in the literature on the epidemiology of CL in pediatric age groups, none have been published in pre-school children (< 5 years of age). In total, 151 children in the pre-school age group were affected, comprising 10.3% of total CL reported during the same period. Gurel and others13 from Turkey reported 19.7% in the 0–4 year age group of the total CL cases, and Bari6 from Pakistan reported 32.3% of total pediatric cases; both percentages are higher than in our study. The high percentage in the winter season, although the patients might have acquired the infection during the preceding summer. The most common site affected was the face (72.18%), which is similar to the finding in the study by Kharfi and others11 (76.5%). Bari6 and Zaraa and others’ reported facial lesions in 98.9% and 88.1% of patients, respectively, which are much higher percentages than in this study. Talari and others10 showed facial lesions in only 47.1% of cases, which is much lower than in all other studies. The occurrence of the majority of lesions on the face observed in our study can be explained by the fact that pre-school children usually spend a lot of time sleeping, and the face is the most frequently exposed body area. The lesions were predominantly plaques and papulonodular, which has been reported in other studies (27.4–78.44%).8,7,10,11 Some of the uncommon morphological forms of CL that were reported earlier in pediatric age groups, including cheilitis, verruciform, perleche, chancriform,8 sporotrichoid, erysipeloid,10 lupoid, mucoucutaneous, and furunculoid,11 were not observed in this study. Microscopic examination of tissue smears and histopathology were confirmatory in 70% and 55.5% of cases, respectively, in this study, whereas Rodrigues and others14 and Al-Hucheimi and others15 reported 66.7% and 66.2% as well as 66.7% and 59.6%, respectively. Newer DNA-based techniques, like PCR, have a higher sensitivity but are expensive and not widely available.16,17

Many treatment modalities have been used in CL in pediatric age groups, including topical, systemic, and physical treatments. Intralesional SSG was used in 58 cases, with a cure rate of 84.4% in this study, whereas Zaraa and others7 and Kharfi and others11 reported cure rates of 67% and 100%, respectively. Oral rifampicin was administered to 50 patients, and the complete cure rate was 82%. Similar results were reported by the same center earlier by Kochchar and others18 and Bumb and Mehta,19 with complete cure in 73.9% and 83.2% of cases, respectively, in all groups. Oral rifampicin was well-tolerated without any serious side effects. It has the advantages of ease of administration, good safety profile, and minimal scarring post-treatment.18,19 Salim and Kandi20 reported complete resolution of lesions in 41 (89.1%) of 46 patients who underwent treatment with oral rifampicin. RFHT is a relatively newer modality for treatment of CL. An Iranian study by Sadeghian and others21 reported a cure rate of > 80% in 117 cases of all age groups with local heat therapy by radiofrequency, whereas Bumb and others22 showed a 94% cure rate. In both studies, RFHT was found to be more effective than intralesional meglumine antimoniate. Similarly, in this study, a cure rate of 92% was observed with RFHT, although it was used in fewer cases and only pre-school children. Dapsone alone or combined with rifampicin was effective in 82.7% cases. A double-blind study assessing the efficacy of oral dapsone by Dogra23 reported a cure rate of 82% with dapsone monotherapy.
In conclusion, *L. tropica* CL is endemic in Bikaner district of the Thar Desert of Rajasthan in the pre-school age group. The clinical and epidemiology spectra seem to be similar to the pediatric and adult age group. Diagnosis in the pre-school age group is based predominantly on clinical presentation and history of stay in endemic areas because of the difficulty in performing invasive investigations and the low sensitivity of skin smear and biopsy. Intralesional SSG remains the standard treatment, but oral rifampicin was observed to be equally efficacious. RFHT is a good alternative because of its minimal systemic toxicity, and only a single treatment session is required compared with other local modalities of treatment. The preventive measures to control the vector have reduced the incidence in the past few years, but more measures should be adopted to reduce the incidence of this infection that can cause facial disfiguration.

Received December 14, 2013. Accepted for publication May 31, 2014.

Authors’ addresses: Saurabh Agrawal, Kanika Khandelwal, and Ram A. Bumb, Department of Dermatology, S P Medical College, Bikaner, Rajasthan, India, E-mails: sagrawal@yahoo.com, khandelwalk@yahoo.com, and dr_bumb@rediffmail.com. Poonam Salotra, Department of Molecular Biology, ICMR, New Delhi, India, E-mail: psalotra@yahoo.com.

REFERENCES


